ISRCTN08435261已完成不适用
Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study
Department of Health (UK)0 个研究点目标入组 150 人开始时间: 2003年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Men aged 50-69 years from specific primary care centres in the three cities were invited to attend a 30-minute prostate check clinic appointment in which they were informed about the study and asked to consent to a prostate specific antigen (PSA) test. Men with a raised PSA (initially =3.0 ng/ml if 50?59 years; =4.0 ng/ml if 60?69 years; but changed to =3.0 ng/ml for all men after 1 year) were invited for biopsy. Men with confirmed localised prostate cancer were invited to participate in a randomised trial of recruitment strategies.
排除标准
- •Men considered by the GP to be unfit for any of the potential treatments (ie those terminally ill or with serious co-morbidity).
研究者
相似试验
招募中
Unknown
Prostate Cancer Screening with short, unenhanced Magnetic Resonance ImagingbpMRI of the prostateDRKS00031035Charité Universitätsmedizin Berlin, Klinik für Radiologie900
招募中
Unknown
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
已完成
不适用
Prostate Cancer Screening Study of 50-75 year old men using the combination test of Circulating Tumour Cells (CTC) and Prostate-Specific MarkersCancer - Prostateprostate cancerACTRN12620000793910AProf Dr Karin Ried300
撤回
不适用
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMCProstate AdenocarcinomaProstate Cancer MetastaticProstate CancerNCT03494803HKGepitherapeutics
招募中
不适用
PROstate cancer follow-up care in Secondary and Primary hEalth Care: PROSPEC study.Prostate cancer, survivorship, primary care, secondary care, follow-up, general practitioner, randomised controlled trialDutch: Prostaatcarcinoom, overlevingszorg, eerstelijnszorg, tweedelijnszorg, nazorg, huisarts, gerandomiseerd gecontroleerde trial.NL-OMON24717Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands390